@JerzakKasia Profile picture

Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC

@JerzakKasia

Medical Oncologist and Lead Breast Oncology Clinical Trials at Sunnybrook Odette Cancer Centre, University of Toronto #breastcancer research #brainmets

Similar User
CCTG photo

@CDNCancerTrials

Dr. Winson Cheung photo

@winsoncheung

Megan E. Tesch photo

@MeganTesch

Lillian Siu photo

@lillian_siu

Maria Jiang photo

@DiMariaJiang

Jonathan Loree photo

@jonathanloree

Erica Tsang photo

@EricaTsangMD

Dr Zachary Veitch photo

@z_veitch

Michael Yan, MD MPH photo

@MichaelYanMD

Brandon Meyers photo

@BrandonMeyersMD

Daniel Vilarim Araujo photo

@DVAraujoMD

Danny Vesprini photo

@dr_vesi

Scott Berry photo

@scottrberry

Michelle Nadler photo

@michellebnadler

Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC Reposted

We are recruiting! Princess Margaret Cancer Centre in Toronto is recruiting an early career cancer research scientist at Assistant Professor level. Apply! Spread the word! nature.com/naturecareers/…


Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC Reposted

‼️🚨ASCO elections are open! 🗳️ Please vote early & make your vote count. 👉🏼I’m delighted to endorse Dr. @ErikaHamilton9 for the Nominating Committee in an undesignated spot in the @ASCO Election for 2025. ⭐️Dr. Hamilton is a world renowned leader in breast cancer drug…

Tweet Image 1

Such a privilege to supervise Dr. Kevin Fan and Dr. Italo Fernandes. Congratulations on your (back-to-back!) oral presentations at #CAMO2024 re: brain metastases 🧠 @CAMO_ACOM @UofT_DoM @Sunnybrook

Tweet Image 1
Tweet Image 2

So nice to meet you @DrSGraff in person @CAMO_ACOM 🇨🇦! Great to hear your perspectives and clinical pearls during our panel discussion. #CAMO2024

An honor to join my Canadian colleagues at @CAMO_ACOM discussing CDK4/6i in HR+/HER2- Breast Cancer #CAMO24

Tweet Image 1
Tweet Image 2


Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC Reposted

Kicking off @CAMO_ACOM #CAMO24 with our breakfast symposium. Hope to see you there! ☕️

Tweet Image 1

Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC Reposted

Join Dr. Moore and myself with a panel of fantastic speakers in #Nashville on Nov 1-2 where we will discuss the latest advances and controversial topics in the field of breast and gynecological cancers #bcsm #gyncsm. Free registration➡️hmpglobalevents.com/gduwo @GreatDebatesCME

Tweet Image 1

Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC Reposted

Look out for our two upcoming October @ISRSy webinars, as young stars in the field presenting. Dr. Roman Kowalchuk @MayoClinic on spine and Dr. Michael Yan @pmcancercentre @UofTDRO on breast oligomet #SBRT

Tweet Image 1

Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC Reposted

Huge day for @Sunnybrook and for neuroscience in Canada and beyond. All thanks to our generous donor community, our government partners, and our incredible Sunnybrook team.

Today, staff in our Hurvitz Brain Sciences Program got a sneak preview of their program’s new home in the Garry Hurvitz Brain Sciences Centre, being unveiled this week before opening to patients in early 2025.

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4


Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC Reposted

1/13 In our new @CD_AACR paper we report an improved strategy to apply immunotherapy to brain metastasis, specially to those that are symptomatic, which has been reported to poorly respond to immune checkpoint blockade antibodies. aacrjournals.org/cancerdiscover…


Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC Reposted

⬇️Lack of data collection rightly infuriates & upsets patients living with secondary BC, & correcting this is a long standing demand by patient groups. Why in technologically modern healthcare systems this simply isn’t standard🤷‍♂️.We’ve estimated for England using available data.

Tweet Image 1

Generally, cancer registries around the world only collect information about initial cancer diagnoses and mortality. Most do not document cancer recurrences that represent the majority of ABC cases and therefore it is currently unknown how many patients with ABC exist. ⚠️⚠️⚠️



It was pleasure to present #breastcancer updates at #CIOC24 including recent data from #ESMO2024 with KN522 showing an OS benefit, as well as intriguing opportunities for treatment escalation & de-escalation. @OncEd

Now up: Dr. Kasia Jerzak from @Sunnybrook providing the latest updates on Breast Cancer #CIOC24 #OncEd

Tweet Image 1


Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC Reposted

Breast cancer knows no boundaries. It affects 1 in 8 women and comes in over 50 distinct forms, touching the lives of Canadians of every age, race, and gender — across all provinces. No two breast cancer journeys are the same. Breast Cancer Canada is dedicated to funding…

Tweet Image 1

Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC Reposted

We are thrilled to share our recent publication in @CellRepMed, in which we explore a phenotypic drug discovery approach to uncover targetable vulnerabilities in brain metastases cell.com/cell-reports-m…


Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC Reposted

8⃣ E Kouzmina @UofTSurgery: Over 8 years, the use of SLNB after neoadjuvant chemotherapy for cN1 breast cancer increased significantly, while ALND decreased, reflecting a shift toward less invasive surgeries @CAGS_ACCG @CAGS_Residents @SocSurgOnc @alilyroberts #CSF2024


Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC Reposted

Dr. Jay Detsky presenting our @Sunnybrook #Glioblastoma UNITED trial as the 1st in the world to perform adaptive weekly on line real-time radiation using the @Elekta Unity @mr_linac We dramatically reduced the CTV to 5mm and showed no disadvantage in marginal failures.

Tweet Image 1

Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC Reposted

Out in JCO: the ratio of enrollment to Industry- vs Federally-sponsored trials doubled between 2008-2022. This led to an acceleration in drug development, but less trials exploring de-escalation or non-drug-related questions. Great editorial by @YAbdouMD ascopubs.org/doi/10.1200/JC…

Tweet Image 1

Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC Reposted

#ESMO24 | Poster 391P |Real-world activity of sacituzumab govitecan for #MetastaticBreastCancer. @StefiMorganti @PTarantinoMD @drsarahsam @prat_aleix @nlinmd @stolaney1 @antgiorda

Tweet Image 1
Tweet Image 2
Tweet Image 3

Katarzyna (Kasia) Jerzak, MD, MSc, FRCPC Reposted

📣 NEW #OncTwitter 🇺🇸 Ribociclib is now FDA-approved for treatment of adults with stage 2 & 3 hormone receptor positive, HER2 negative #breastcancer at high risk of recurrence based on efficacy & safety results of the NATALEE trial. #bcsm #regulatory #ESMO24


Wow. "The cumulative incidence of CNS progression at 12 months was 9% (95% CI 5% to 14%) with osimertinib and 36% (95% CI 24% to 47%) with placebo." 🧠 Prevention/delay of #CNSmetastases is an important endpoint for patients.

📢 #ESMO24 concomitant paper: Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: CNS efficacy and distant progression from the ph III LAURA study #ESMO24 #osimertinib #NSCLC @RamalingamMD tinyurl.com/2434sn7f Dr Shun Lu introduces the LAURA study



Great to meet my ASCO mentee Dr.Cassio Hidalgo Filho from Brazil 🇧🇷 in person! #ESMO2024

Tweet Image 1

Loading...

Something went wrong.


Something went wrong.